Preparation of heterocyclic Met kinase inhibitors for use in treating cancer.

Abstract

The present invention is directed to compds. having the formula I or II (wherein R1 is H, halo, halogenated alkyl, etc.; A is substituted pyrimidine, etc.; B is O, S, etc.; W and X are C or N; V is CO; Y is (un)substituted Ph, (un)substituted pyridine, etc.; n is 1-4; p is 0-2; R2 is H, (un)substituted alkyl, or (un)substituted cycloalkyl; R3 and R4 are H, halogen, (un)substituted alkyl, etc. or taken together form a carbocyclic or heterocyclic ring; R5 is (un)substituted alkyl, haloalkyl, cycloalkyl, etc.) including salts thereof, and methods for using them for the treatment of cancer. Example compd. III was prepd. by reacting 4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)-3-fluorobenzenamine (prepn. given) and 4-chloro-N-(2,4-difluorophenyl)nicotinamide (prepn. given). No biol. data is given in the patent. [on SciFinder(R)]